(NASDAQ: ELVN) Enliven Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.72%.
Enliven Therapeutics's earnings in 2025 is -$94,830,000.On average, 3 Wall Street analysts forecast ELVN's earnings for 2025 to be -$104,679,448, with the lowest ELVN earnings forecast at -$106,480,290, and the highest ELVN earnings forecast at -$102,554,749. On average, 2 Wall Street analysts forecast ELVN's earnings for 2026 to be -$117,766,219, with the lowest ELVN earnings forecast at -$118,747,604, and the highest ELVN earnings forecast at -$116,784,834.
In 2027, ELVN is forecast to generate -$176,158,636 in earnings, with the lowest earnings forecast at -$176,158,636 and the highest earnings forecast at -$176,158,636.